Calcium Acetate Granules Fluidized Bed Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current phosphate binders for treating hyperphosphatemia and hypercalcemia associated with renal insufficiency have chemical instability, poor reproducibility, and inadequate particle size control, leading to ineffective treatment and safety concerns due to aluminum-based compounds and insufficient efficacy of sevelamer hydrochloride, while combination preparations with calcium acetate and magnesium carbonate suffer from decomposition issues.
Innovation Solution
A process using fluidized bed granulation to produce particulate calcium acetate granules, which are then mixed with magnesium salt components to create a stable and reproducible composition, enhancing chemical stability, storage life, and active ingredient release profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If tray drying is used to produce calcium acetate granules, then the manufacturing process is simple, but the chemical stability is poor and decomposition occurs
Solution Approach 1:
The patent changes the manufacturing parameters from tray drying to fluidized bed granulation, which controls particle formation and drying more effectively. This prevents decomposition while maintaining manufacturing feasibility through standardized process parameters
Solution Approach 2:
The patent replaces the mechanical tray drying system with a fluidized bed system that uses fluid dynamics to achieve uniform particle coating and drying. This substitution prevents hot spots and decomposition while maintaining ease of manufacture through automated control
2Ease of manufacture
If tray drying is used to produce calcium acetate granules, then the manufacturing process is straightforward, but the reproducibility is poor and particle size control is inadequate
Solution Approach 1:
The patent changes the granulation process parameters by implementing fluidized bed technology with controlled fluidization velocity, spray rate, and particle residence time. These parameter changes enable precise particle size control while maintaining manufacturing straightforwardness through automated process control
Solution Approach 2:
The patent implements feedback control in the fluidized bed granulation process, where particle size distribution is monitored and process parameters are adjusted accordingly. This ensures reproducible particle size control while maintaining ease of manufacture through self-regulating process dynamics
3Reliability
If combination preparations of calcium acetate and magnesium carbonate are used, then the treatment efficacy is improved, but decomposition issues arise reducing stability
Solution Approach 1:
The patent segments the combination preparation into separately granulated calcium acetate and magnesium carbonate components that are mixed only in the final formulation stage. This segmentation prevents premature decomposition while maintaining treatment efficacy by preserving the chemical integrity of each active ingredient
Solution Approach 2:
The patent extracts the decomposition problem by separating the calcium acetate and magnesium carbonate manufacturing processes. Each component is produced and stabilized independently through fluidized bed granulation, then combined in controlled proportions to form the final stable formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process results in a composition with improved chemical stability, enhanced storage stability, and optimized active ingredient release, effectively treating hyperphosphatemia and hypercalcemia with increased bulk density and flowability, reducing the risk of side effects and improving treatment efficacy.
Implementation Method 1
A process using fluidized bed granulation to produce particulate calcium acetate granules
Data Source
AI summary
Preparing a composition, preferably a medicament, comprising a combination of calcium acetate and magnesium salts, comprises: (a) providing particulate calcium acetate granulate, which is produced by fluidized bed granulation; (b) providing a particulate magnesium salt component; (c) producing a mixture using the calcium acetate granulate and the magnesium salt component; and (d) processing the produced mixture to an administrable product, preferably orally administrable formulation, preferably medicament form. Independent claims are included for: (1) the composition, preferably medicament, obtained by the above process; (2) a process for producing particulate calcium acetate, in which the calcium acetate is produced in the form of calcium acetate granulates by fluidized bed granulation; and (3) a particulate calcium acetate, obtained in the form of calcium acetate granulate using fluidized bed granulation. ACTIVITY : Nephrotropic; Metabolic; Cardiovascular-Gen.; CNS-Gen.; Gastrointestinal-Gen. MECHANISM OF ACTION : None given.